Figure 5. Kaplan-Meier estimation of OS and DFS in AML patients.
AML Patients were enrolled in decitabine prior to HAA (n = 23) or HAA alone (n = 24). Patients were followed up to 36 months for OS (p = 0.043) and DFS (p = 0.023) shown in Figure 5A and 5B.